Podbit · God Mode Podcast
Donald Knuth — the most credible AI skeptic in computer science — just publicly reversed his position. Claude Opus solved in one hour a problem Knuth had been stuck on for six to eight weeks. The model didn't just answer the question — it used creative, novel approaches. The floor just moved for everyone whose job is to think hard.
Where this was said
At 32:52 · chapter starts 1:42
Anthropic research shows AI can theoretically handle 70–80% of tasks in management, legal, and healthcare sectors.
Despite high theoretical capability, real-world AI usage in top industries sits at only around 30%, leaving a massive 50-point gap.
AI can theoretically automate 70–80% of tasks in management, legal, and healthcare. Real-world adoption sits at 30%. That 50-point gap is not a problem — it's the largest untapped opportunity in the market right now. The biggest deltas between capability and adoption are exactly where you should be building.
Legal and healthcare have the biggest gaps between AI capability and adoption for a reason: the stakes. One hallucinated citation can get a lawyer disbarred. One hallucinated dosage is malpractice. The risk-reward ratio is brutal, and until AI proves it's more accurate than humans, adoption will stay slow.
The US government is making national security decisions with Claude 3.5 Sonnet — a model over seven months old — while consumers use Claude 4.6 Opus. The models arrive on physical 1TB drives to air-gapped systems. Meanwhile, China distills frontier models through mass API calls and deploys the latest versions to its own government. The US is a year behind.
Social norms compress behavior so effectively that we assume other minds are similar to ours. They almost never are. After running over 100 psychology studies, Greenberg's biggest finding is that humans are far more different from each other than we intuitively believe.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.